3SBio, Inc. is a pioneer in the biotechnology industry in China. The Company is engaged in developing, manufacturing and marketing biopharmaceuticals, The Company's core products are the following: TPIAO, approved by the CFDA for two indications: the treatment of chemotherapy-induced thrombocytopenia (“CIT”) and the treatment of immune thrombocytopenia (“ITP”); and EPIAO, approved by the CFDA for three indications: the treatment of anemia associated with chronic kidney disease (“CKD”), the treatment of chemotherapy-induced anemia (“CIA”) and the reduction of allogeneic blood transfusion in surgery patients. The Company was incorporated in 2006 and is headquartered in Hong Kong.
Headquarters
No. 3 A1, Road 10, Shenyang Economy And Technology Development Zone
Shenyang; Liaoning;
Contact Details: Purchase the 3SBio Inc. (三生制药) report to view the information.
Website: http://www.3sbio.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service